Xilio Therapeutics (NASDAQ:XLO) Stock Price Up 1%

Xilio Therapeutics, Inc. (NASDAQ:XLO)’s stock price was up 1% during trading on Wednesday . The stock traded as high as $1.11 and last traded at $1.06. Approximately 297,031 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 1,045,277 shares. The stock had previously closed at $1.05.

Xilio Therapeutics Trading Up 7.9 %

The company has a market cap of $37.57 million, a price-to-earnings ratio of -0.39 and a beta of -0.12. The business’s 50 day moving average price is $0.92 and its 200-day moving average price is $1.03.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Monday, April 1st. The company reported ($0.64) earnings per share (EPS) for the quarter. Equities research analysts forecast that Xilio Therapeutics, Inc. will post -1.53 EPS for the current fiscal year.

Insider Activity at Xilio Therapeutics

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. bought 485,250 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were bought at an average cost of $0.76 per share, with a total value of $368,790.00. Following the completion of the acquisition, the insider now owns 7,345,473 shares of the company’s stock, valued at $5,582,559.48. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC purchased a new position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned approximately 0.09% of Xilio Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.